Pharmacotherapeutic group: Immunosuppressants, selective immunosuppressants.
ATC code: L04AA44.
Pharmacology: Pharmacodynamics: Mechanism of Action: Upadacitinib is a selective and reversible Janus Kinase (JAK) inhibitor. JAKs are intracellular enzymes that transmit cytokine or growth factor signals involved in a broad range of cellular processes including inflammatory responses, hematopoiesis and immune surveillance. The JAK family of enzymes contains four members, JAK1, JAK2, JAK3 and TYK2 which work in pairs to phosphorylate and activate signal transducers and activators of transcription (STATs). This phosphorylation, in turn, modulates gene expression and cellular function. JAK1 is important in inflammatory cytokine signals while JAK2 is important for red blood cell maturation and JAK3 signals play a role in immune surveillance and lymphocyte function.
In human cellular assays, upadacitinib preferentially inhibits signalling by JAK1 or JAK1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2. Atopic dermatitis is driven by pro-inflammatory cytokines (including IL-4, IL-13, IL-22, TSLP, IL-31 and IFN-γ) that transduce signals via the JAK1 pathway. Inhibiting JAK1 with upadacitinib reduces the signaling of many mediators which drive the signs and symptoms of atopic dermatitis such as eczematous skin lesions and pruritus. Pro-inflammatory cytokines (primarily IL-6, IL-7, IL-15 and IFNγ) transduce signals via the JAK1 pathway and are involved in ulcerative colitis pathogenesis. JAK1 inhibition with upadacitinib modulates the signaling of the JAK-dependent cytokines underlying the inflammatory burden and signs and symptoms of ulcerative colitis.
Pharmacodynamic effects: Inhibition of IL-6 Induced STAT3 and IL-7 Induced STAT5 Phosphorylation: In healthy volunteers, the administration of upadacitinib (immediate release formulation) resulted in a dose- and concentration-dependent inhibition of IL-6 (JAK1/JAK2)-induced STAT3 and IL-7 (JAK1/JAK3)-induced STAT5 phosphorylation in whole blood. The maximal inhibition was observed 1 hour after dosing which returned to near baseline by the end of dosing interval.
Lymphocytes: In patients with rheumatoid arthritis, treatment with upadacitinib was associated with a small, transient increase in mean ALC from baseline up to Week 36 which gradually returned to at or near baseline levels with continued treatment.
hsCRP: In patients with rheumatoid arthritis, treatment with upadacitinib was associated with decreases from baseline in mean hsCRP levels as early as Week 1 which were maintained with continued treatment.
Vaccine Studies: The influence of upadacitinib on the humoral response following administration of adjuvanted recombinant glycoprotein E herpes zoster vaccine was evaluated in 93 patients with rheumatoid arthritis under stable treatment with upadacitinib 15 mg. 98% of patients (n=91) were on concomitant methotrexate. 49% of patients were on oral corticosteroids at baseline. Vaccination resulted in a satisfactory humoral response, 4 weeks post vaccination dose 2, in 88% (95% CI: 81.0, 94.5) of patients treated with upadacitinib 15 mg.
The influence of upadacitinib on the humoral response following the administration of pneumococcal 13-valent conjugate vaccine was evaluated in 111 patients with rheumatoid arthritis under stable treatment with upadacitinib 15 mg (n=87) or 30 mg (n=24). 97% of patients (n=108) were on concomitant methotrexate. Vaccination resulted in a satisfactory humoral response in 67.5% (95% CI: 57.4, 77.5) and 56.5% (95% CI: 36.3, 76.8) of patients treated with upadacitinib 15 mg and 30 mg, respectively.
Clinical efficacy and safety: Rheumatoid Arthritis: The efficacy and safety of upadacitinib 15 mg once daily was assessed in five Phase 3 randomised, double-blind, multicentre studies in patients with moderately to severely active rheumatoid arthritis and fulfilling the ACR/EULAR 2010 classification criteria (see Table 1). Patients 18 years of age and older were eligible to participate. The presence of at least 6 tender and 6 swollen joints and evidence of systemic inflammation based on elevation of hsCRP was required at baseline. Four studies included long-term extensions for up to 5 years, and one study (SELECT-COMPARE) included a long-term extension for up to 10 years.
The primary analysis for each of these studies included all randomised subjects who received at least 1 dose of study drug, and non-responder imputation was used for categorical endpoints.
Across the Phase 3 studies, the efficacy seen with upadacitinib 15 mg QD was generally similar to that observed with upadacitinib 30 mg QD. (See Table 1.)
Click on icon to see table/diagram/image
Clinical Response: Remission and low disease activity: In the studies, a significantly higher proportion of patients treated with upadacitinib 15 mg achieved low disease activity (DAS28-CRP ≤3.2) and clinical remission (DAS28-CRP <2.6) compared to placebo, MTX or adalimumab (Table 2). Compared to adalimumab, significantly higher rates of low disease activity were achieved at week 12 in SELECT-COMPARE. Overall, both low disease activity and clinical remission rates were consistent across patient populations, with or without MTX, and were maintained through 3 years based on available long-term extension study results.
ACR Response: In all studies, more patients treated with upadacitinib 15 mg achieved ACR20, ACR50, and ACR70 responses at 12 weeks compared to placebo, MTX, or adalimumab (Table 2). Time to onset of efficacy was rapid across measures with greater responses seen as early as Week 1 for ACR20. Durable response rates were observed (with or without MTX), with ACR20/50/70 responses maintained through 3 years based on available long-term extension study results.
Treatment with upadacitinib 15 mg, alone or in combination with csDMARDs, resulted in improvements in individual ACR components, including tender and swollen joint counts, patient and physician global assessments, HAQ-DI, pain assessment and hsCRP. (See Table 2.)
Click on icon to see table/diagram/image
Radiographic Response: Inhibition of progression of structural joint damage was assessed using the modified Total Sharp Score (mTSS) and its components, the erosion score and joint space narrowing score, at Weeks 24/26 and Week 48 in SELECT-EARLY and SELECT-COMPARE.
Treatment with upadacitinib 15 mg resulted in significantly greater inhibition of the progression of structural joint damage compared to placebo in combination with MTX in SELECT-COMPARE and as monotherapy compared to MTX in SELECT-EARLY (Table 3). Analyses of erosion and joint space narrowing scores were consistent with the overall scores. The proportion of patients with no radiographic progression (mTSS change ≤ 0) was significantly higher with upadacitinib 15 mg in both studies. Inhibition of progression of structural joint damage was maintained through Week 96 in both studies for patients receiving RINVOQ 15 mg. (See Table 3.)
Click on icon to see table/diagram/image
Physical Function Response and Health-Related Outcomes: Treatment with upadacitinib 15 mg, alone or in combination with csDMARDs, resulted in a significantly greater improvement in physical function compared to all comparators as measured by HAQ-DI (see Table 4).
Click on icon to see table/diagram/image
Improvement in HAQ-DI was maintained through 3 years for patients receiving upadacitinib 15 mg based on available results from SELECT-COMPARE and SELECT-EARLY.
In the studies SELECT-MONOTHERAPY, SELECT-NEXT, and SELECT-COMPARE, treatment with upadacitinib 15 mg resulted in a significantly greater improvement in the mean duration of morning joint stiffness compared to placebo or MTX.
In the clinical studies, upadacitinib treated patients reported significant improvements in patient-reported quality of life, as measured by the Short Form (36) Health Survey (SF-36) Physical Component Summary compared to placebo and MTX. Moreover, upadacitinib treated patients reported significant improvements in fatigue, as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue score (FACIT-F) compared to placebo.
Psoriatic Arthritis: The efficacy and safety of RINVOQ 15 mg once daily was assessed in two Phase 3 randomized, double-blind, multicenter, placebo-controlled studies in patients 18 years of age or older with moderately to severely active psoriatic arthritis (Table 5). All patients had active psoriatic arthritis for at least 6 months based upon the Classification Criteria for Psoriatic Arthritis (CASPAR), at least 3 tender joints and at least 3 swollen joints, and active plaque psoriasis or history of plaque psoriasis. The studies include long-term extensions for up to 5 years (SELECT-PsA 1) and 3 years (SELECT-PsA 2). (See Table 5.)
Click on icon to see table/diagram/image
Clinical Response: In both studies, a significantly greater proportion of patients treated with RINVOQ 15 mg achieved ACR20 response compared to placebo at Week 12 (Table 6, Figure 1). In SELECT-PsA 1, RINVOQ 15 mg achieved non-inferiority compared to adalimumab in the proportion of patients achieving ACR20 response at Week 12. A higher proportion of patients treated with RINVOQ 15 mg achieved ACR50 and ACR70 responses at Week 12 compared to placebo. Time to onset of efficacy was rapid across measures with greater responses seen as early as Week 2 for ACR20.
Treatment with RINVOQ 15 mg resulted in improvements in individual ACR components, including tender/painful and swollen joint counts, patient and physician global assessments, HAQ-DI, pain assessment, and hsCRP compared to placebo (Table 7).
In both studies, consistent responses were observed alone or in combination with non-biologic DMARDs for primary and key secondary endpoints.
The efficacy of RINVOQ 15 mg was demonstrated regardless of subgroups evaluated including baseline BMI, baseline hsCRP, and number of prior non-biologic DMARDs (≤ 1 or >1). (See Figure 1, Tables 6 and 7.)
Click on icon to see table/diagram/image
Click on icon to see table/diagram/image
Click on icon to see table/diagram/image
In both studies, response rates for ACR20/50/70, MDA, PASI75/90/100, sIGA, enthesitis resolution, and dactylitis resolution in patients treated with RINVOQ 15 mg were maintained through Week 56.
Radiographic Response: In SELECT-PsA 1, inhibition of progression of structural damage was assessed radiographically and expressed as the change from baseline in modified Total Sharp Score (mTSS) and its components, the erosion score and the joint space narrowing score, at Week 24.
Treatment with RINVOQ 15 mg resulted in significantly greater inhibition of the progression of structural joint damage compared to placebo at Week 24 (Table 8). Erosion and joint space narrowing scores were consistent with the overall scores. The proportion of patients with no radiographic progression (mTSS change ≤ 0.5) was higher with RINVOQ 15 mg compared to placebo at Week 24. (See Table 8.)
Click on icon to see table/diagram/image
Physical Function Response and Health-Related Outcomes: In both studies, patients treated with RINVOQ 15 mg showed significant improvement in physical function from baseline compared to placebo as assessed by HAQ-DI at Week 12 (Table 7), which was maintained through Week 56.
The proportion of HAQ-DI responders (≥ 0.35 improvement from baseline in HAQ-DI score) at Week 12 in SELECT-PsA 1 and SELECT-PsA 2 was 58% and 45%, respectively, in patients receiving RINVOQ 15 mg, 33% and 27%, respectively, in patients receiving placebo, and 47% in patients receiving adalimumab (SELECT-PsA 1).
Health-related quality of life was assessed by SF-36. In both studies, patients receiving RINVOQ 15 mg experienced significantly greater improvement from baseline in the Physical Component Summary score compared to placebo at Week 12. Improvements from baseline were maintained through Week 56 in both studies.
Patients receiving RINVOQ 15 mg experienced significantly greater improvement from baseline in fatigue, as measured by FACIT-F score, at Week 12 compared to placebo in both studies. Improvements from baseline were maintained through Week 56 in both studies.
SAPS change from baseline at Week 16 in SELECT-PsA 1 and SELECT-PsA 2 were -25.3 (95% CI: -27.3, -23.4) and -24.4 (95% CI: -27.5, -21.2), respectively, in patients receiving RINVOQ 15 mg, and -8.2 (95% CI: -10.2, -6.3) and -1.5 (95% CI: -4.7, 1.8), respectively, in patients receiving placebo.
Among patients with psoriatic spondylitis, in both studies patients treated with RINVOQ 15 mg showed improvements from baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) compared to placebo at Week 24. Improvements from baseline were maintained through Week 56 in both studies.
Non-radiographic Axial Spondyloarthritis: The efficacy and safety of RINVOQ 15 mg once daily were assessed in a randomized, double-blind, multicenter, placebo-controlled study in patients 18 years of age or older with active non-radiographic axial spondyloarthritis based upon the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥ 4, Patient's Assessment of Total Back Pain score ≥ 4, and objective signs of inflammation (Table 9). The study included a long-term extension for up to 2 years. (See Table 9.)
Click on icon to see table/diagram/image
Clinical Response: In SELECT-AXIS 2 (STUDY 2), a significantly greater proportion of patients treated with RINVOQ 15 mg achieved an ASAS40 response compared to placebo at Week 14 (Table 10, Figure 2). Time to onset of efficacy was rapid across measures with greater responses seen as early as Week 2 for ASAS40.
Treatment with RINVOQ 15 mg resulted in greater improvement in individual ASAS components (patient global assessment of disease activity, total back pain assessment, inflammation, and function) and other measures of disease activity, including BASDAI compared to placebo at Week 14.
The efficacy of RINVOQ 15 mg was demonstrated across subgroups including gender, baseline BMI, symptom duration of non-radiographic axial spondyloarthritis, baseline hsCRP, MRI sacroiliitis, and prior use of bDMARDs. (See Figure 2, Tables 10 and 11.)
Click on icon to see table/diagram/image
Click on icon to see table/diagram/image
Click on icon to see table/diagram/image
Physical Function Response and Health-Related Outcomes: Patients treated with RINVOQ 15 mg showed significant improvement in physical function from baseline compared to placebo as assessed by the BASFI at Week 14 (Table 11).
Patients treated with RINVOQ 15 mg showed significant improvements in total back pain and nocturnal back pain compared to placebo at Week 14. These improvements were observed as early as Week 2 for total back pain and Week 4 for nocturnal back pain.
Patients treated with RINVOQ 15 mg showed significant improvements in health-related quality of life and overall health as measured by Ankylosing Spondylitis Quality of Life (ASQoL) and ASAS Health Index, respectively, compared to placebo at Week 14.
Patients treated with RINVOQ 15 mg experienced greater improvement from baseline in fatigue as measured by FACIT-F score compared to placebo at Week 14.
Enthesitis: Patients with pre-existing enthesitis treated with RINVOQ 15 mg showed greater improvement in enthesitis compared to placebo as measured by change from baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at week 14.
Objective Measures of Inflammation: Signs of inflammation were assessed by MRI and expressed as change from baseline in the SPARCC score. Improvement of inflammatory signs in both sacroiliac joints and the spine was observed in patients treated with upadacitinib 15 mg. At Week 14, significant improvement of inflammatory signs in the sacroiliac joints was observed in patients treated with upadacitinib 15 mg compared to placebo.
Ankylosing Spondylitis: The efficacy and safety of RINVOQ 15 mg once daily were assessed in two randomized, double-blind, multicenter, placebo-controlled studies in patients 18 years of age or older with active ankylosing spondylitis based upon the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥4 and Patient's Assessment of Total Back Pain score ≥4 (Table 12). Both studies included a long-term extension for up to 2 years. (See Table 12.)
Click on icon to see table/diagram/image
Clinical Response: In both studies, a significantly greater proportion of patients treated with RINVOQ 15 mg achieved an ASAS40 response compared to placebo at Week 14 (Table 13, Figures 3 and 4). Time to onset of efficacy was rapid across measures with greater responses seen as early as Week 2 in SELECT-AXIS 1 and Week 4 in SELECT-AXIS 2 (STUDY 1) for ASAS40.
Treatment with RINVOQ 15 mg resulted in improvements in individual ASAS components, (patient global assessment of disease activity, total back pain assessment, inflammation, and function) and other measures of disease activity, including BASDAI at Week 14 compared to placebo (Table 14).
The efficacy of RINVOQ 15 mg was demonstrated regardless of subgroups evaluated including gender, baseline BMI, symptom duration of ankylosing spondylitis, baseline hsCRP, and prior use of bDMARDs. (See Figures 3, 4 and Table 13.)
Click on icon to see table/diagram/image
Click on icon to see table/diagram/image
Click on icon to see table/diagram/image
In SELECT-AXIS 1, efficacy was maintained through 2 years as assessed by the endpoints presented in Table 13.
Click on icon to see table/diagram/image
Physical Function Response and Health-Related Outcomes: In both studies, patients treated with RINVOQ 15 mg showed significant improvement in physical function from baseline compared to placebo as assessed by the BASFI at Week 14 (Table 14).
In SELECT-AXIS 1, patients treated with RINVOQ 15 mg showed greater improvement in back pain as assessed by the Total Back Pain component of ASAS response and nocturnal back pain compared to placebo at Week 14.
In SELECT-AXIS 2 (STUDY 1), patients treated with RINVOQ 15 mg showed significant improvements in total back pain and nocturnal back pain compared to placebo at Week 14. These improvements were observed as early as Week 1 for total back pain and Week 2 for nocturnal back pain.
In both studies, improvement in the overall level of neck, back, or hip pain was demonstrated using BASDAI Question 2. Improvements were also demonstrated for peripheral pain and swelling (assessed by BASDAI question 3 on overall pain in joints other than in the neck, back, or hips). Improvements in total and nocturnal back pain were observed as early as Week 2.
In SELECT-AXIS 1, improvements in BASFI and pain were maintained through 2 years for patients receiving RINVOQ 15 mg.
In SELECT-AXIS 2 (STUDY 1), patients treated with RINVOQ 15 mg showed significant improvements in health-related quality of life and overall health as measured by ASQoL and ASAS Health Index, respectively, compared to placebo at Week 14. Improvements in ASQoL and ASAS Health Index were also observed in SELECT-AXIS 1 compared to placebo at Week 14.
In SELECT-AXIS 2 (STUDY 1), patients treated with RINVOQ 15 mg experienced greater improvement from baseline in fatigue as measured by FACIT-F score compared to placebo at Week 14.
Enthesitis: In SELECT-AXIS 2 (STUDY 1), patients with pre-existing enthesitis treated with RINVOQ 15 mg showed significant improvement in enthesitis compared to placebo as measured by change from baseline in MASES at week 14. Improvements in MASES were also observed in SELECT-AXIS 1 compared to placebo at Week 14.
Spinal mobility: In SELECT-AXIS 2 (STUDY 1), patients treated with RINVOQ 15 mg showed significant improvement in spinal mobility compared to placebo as measured by change from baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) at Week 14. Improvements in BASMI were also observed in SELECT-AXIS 1 compared to placebo at Week 14.
Objective Measures of Inflammation: Signs of inflammation were assessed by MRI and expressed as change from baseline in the SPARCC score for spine and sacroiliac joints. In both studies, at Week 14, significant improvement of inflammatory signs in the spine was observed in patients treated with RINVOQ 15 mg compared to placebo. Additionally, patients treated with RINVOQ 15 mg demonstrated greater improvement of inflammatory signs in sacroiliac joints compared to placebo. In SELECT-AXIS 1, improvement in inflammation as assessed by MRI was maintained through 2 years.
Atopic Dermatitis: The efficacy and safety of RINVOQ 15 mg and 30 mg once daily was assessed in three Phase 3 randomized, double-blind, multicenter studies (MEASURE UP 1, MEASURE UP 2 and AD UP) in a total of 2584 patients 12 years of age and older (Table 15). RINVOQ was evaluated in 344 adolescent and 2240 adult patients with moderate to severe atopic dermatitis (AD) not adequately controlled by topical medication(s). At baseline, patients had to have all the following: an Investigator's Global Assessment (vIGA-AD) score ≥3 in the overall assessment of AD (erythema, induration/papulation, and oozing/crusting) on an increasing severity scale of 0 to 4, an Eczema Area and Severity Index (EASI) score ≥16 (composite score assessing extent and severity of erythema, edema/papulation, scratches and lichenification across 4 different body sites), a minimum body surface area (BSA) involvement of ≥10%, and weekly average Worst Pruritus Numerical Rating Scale (NRS) ≥4.
In all three studies, patients received RINVOQ once daily doses of 15 mg, 30 mg or matching placebo for 16 weeks. In the AD UP study, patients also received concomitant topical corticosteroids (TCS). Following completion of the double-blinded period, patients originally randomized to RINVOQ were to continue receiving the same dose until week 136. Patients in the placebo group were re-randomized in a 1:1 ratio to receive RINVOQ 15 mg or 30 mg until week 136. (See Table 15.)
Click on icon to see table/diagram/image
Clinical Response: Monotherapy Studies (MEASURE UP 1 AND MEASURE UP 2): In the MEASURE UP studies, a significantly greater proportion of patients treated with RINVOQ 15 mg or 30 mg achieved vIGA-AD 0 or 1 response and achieved EASI 75 compared to placebo at week 16 (Table 16). A rapid improvement in skin clearance (defined as EASI 75 by Week 2) was achieved for both doses compared to placebo (p < 0.001).
A significantly greater proportion of patients treated with RINVOQ 15 mg or 30 mg achieved clinically meaningful improvement in itch (defined as a ≥ 4-point reduction in the Worst Pruritus NRS) compared to placebo at week 16. Rapid improvement in itch (defined as a ≥ 4-point reduction in Worst Pruritus NRS by Week 1) was achieved for both doses compared to placebo (p < 0.001), with differences observed as early as 1 day after initiating RINVOQ 30 mg (Day 2, p < 0.001) and 2 days after initiating RINVOQ 15 mg (Day 3, p < 0.001).
A significantly smaller proportion of patients treated with RINVOQ 15 mg or 30 mg had a disease flare, defined as a clinically meaningful worsening of disease (increase in EASI by ≥ 6.6), during the initial 16 weeks of treatment compared to placebo (p < 0.001).
Figure 5 and Figure 6 show proportion of patients achieving an EASI 75 response and the proportion of patients with ≥4-point improvement in the Worst Pruritus NRS, respectively up to Week 16. (See Table 16, Figures 5 and 6.)
Click on icon to see table/diagram/image
Click on icon to see table/diagram/image
Click on icon to see table/diagram/image
In both studies, results at week 16 continued to be observed through Week 52 in patients treated with RINVOQ 15 mg or 30 mg.
Treatment effects in subgroups (weight, age, gender, race, and prior systemic treatment with immunosuppressants) in both studies were consistent with the results in the overall study population.
Concomitant TCS Study (AD UP): In AD UP, a significantly greater proportion of patients treated with RINVOQ 15 mg + TCS or 30 mg + TCS achieved vIGA-AD 0 or 1 response and achieved EASI 75 compared to placebo + TCS at week 16 (Table 17). A rapid improvement in skin clearance (defined as EASI 75 by Week 2) was achieved for both doses compared to placebo + TCS (p < 0.001). In addition, a higher EASI 90 response rate was achieved at week 4 for both doses compared to placebo + TCS (p < 0.001).
A significantly greater proportion of patients treated with RINVOQ 15 mg + TCS or 30 mg + TCS achieved a clinically meaningful improvement in itch (defined as a ≥ 4-point reduction in the Worst Pruritus NRS) compared to placebo + TCS at week 16. A rapid improvement in itch (defined as a ≥ 4-point reduction in Worst Pruritus NRS by Week 1) was achieved for both doses compared to placebo + TCS (p < 0.001).
Figure 7 and Figure 8 show proportion of patients achieving an EASI 75 response and the proportion of patients with ≥4-point improvement in the Worst Pruritus NRS, respectively up to Week 16. (See Table 17, Figures 7 and 8.)
Click on icon to see table/diagram/image
Click on icon to see table/diagram/image
Click on icon to see table/diagram/image
Treatment effects in subgroups (weight, age, gender, race, and prior systemic treatment with immunosuppressants) in AD UP were consistent with the results in the overall study population.
Subjects treated with either RINVOQ 15 mg or 30 mg had significantly more days free of TCS use with a concurrent EASI 75 response (mean: 33.5 and 47.5 days, respectively) over the 16-week period, compared to placebo group (mean: 7.9 days).
Results at Week 16 continued to be observed through Week 52 in patients treated with RINVOQ 15 mg or 30 mg.
Quality of Life/Patient-reported outcomes: In the MEASURE UP studies, a significantly greater proportion of patients treated with RINVOQ 15 mg or 30 mg reported clinically meaningful reductions in the symptoms of AD and the impact of AD on health-related quality of life compared to placebo at week 16 (Table 18). A significantly greater proportion of patients treated with RINVOQ achieved clinically meaningful reductions in AD symptom severity as measured by ADerm-SS TSS-7 and ADerm-SS Skin Pain compared to placebo at week 16. A greater proportion of patients treated with RINVOQ achieved clinically meaningful reductions in the patient-reported effects of AD on sleep, daily activities and emotional state as measured by the ADerm-IS domain scores compared to placebo at week 16. Similarly, compared to placebo at week 16, a greater proportion of patients treated with RINVOQ achieved clinically meaningful improvements in AD symptom frequency and health-related quality of life as measured by the POEM and DLQI.
Anxiety and depression symptoms as measured by the HADS score were significantly reduced; in patients with baseline HADS-anxiety or HADS-depression subscale scores ≥ 8 (the cut-off value for anxiety or depression), a greater proportion of patients in the RINVOQ 15 mg or 30 mg groups achieved HADS-anxiety and HADS-depression scores < 8 at week 16 compared to placebo (see Table 18).
Click on icon to see table/diagram/image
Adolescent population: A total of 344 adolescents aged 12 to 17 years with moderate to severe atopic dermatitis were randomized across the three Phase 3 studies to receive either 15 mg (N=114) or 30 mg (N=114) RINVOQ or matching placebo (N=116), in monotherapy or combination with topical corticosteroids. Efficacy was consistent between the adolescents and adults (Table 19). The adverse event profile in adolescents was generally similar to that in adults. (See Table 19.)
Click on icon to see table/diagram/image
Ulcerative Colitis: The efficacy and safety of RINVOQ was evaluated in three multicenter, double-blind, placebo-controlled Phase 3 clinical studies: two replicate induction studies, UC-1 and UC-2, and a maintenance study UC-3.
Disease activity was based on the adapted Mayo score (aMS, Mayo scoring system excluding Physician's Global Assessment), which ranged from 0 to 9 and has three subscores that were each scored 0 (normal) to 3 (most severe): stool frequency subscore (SFS), rectal bleeding subscore (RBS), and a centrally-reviewed endoscopy subscore (ES). (See Table 20.)
Click on icon to see table/diagram/image
Induction studies (UC-1 and UC-2): In studies UC-1 and UC-2, 988 patients (473 and 515 patients, respectively) were randomized to RINVOQ 45 mg once daily or placebo for 8 weeks with a 2:1 treatment allocation ratio and included in the efficacy analysis. All enrolled patients had moderately to severely active ulcerative colitis defined as aMS of 5 to 9 with an ES of 2 or 3 and demonstrated prior treatment failure including inadequate response, loss of response, or intolerance to prior conventional and/or biologic treatment. Prior treatment failure to at least 1 biologic therapy (Prior biologic failure) was seen in 52% (246/473) and 51% (262/515) of patients, respectively. Previous treatment failure to conventional therapy but not biologics (Without prior biologic failure) was seen in 48% (227/473) and 49% (253/515) of patients, respectively.
At Baseline in UC-1 and UC-2, 39% and 37% of patients received corticosteroids, 1.1% and 0.6% of patients received methotrexate and 68% and 69% of patients received aminosalicylates. Concomitant use of thiopurine was not allowed during the studies. Patient disease activity was moderate (aMS ≥5, ≤7) in 61% and 60% of patients and severe (aMS >7) in 39% and 40% of patients.
Results of the primary endpoint of clinical remission at Week 8 and secondary endpoints are listed in Table 21. (See Table 21.)
Click on icon to see table/diagram/image
Disease Activity and Symptoms: A significantly greater proportion of patients treated with RINVOQ 45 mg once daily compared to placebo had no abdominal pain or no bowel urgency at Week 8 (see Table 21).
For patients with baseline corticosteroid treatment, clinical remission at Week 8 was achieved in 26.5% of patients treated with RINVOQ 45 mg once daily and 4.0% with placebo, and for patients without baseline corticosteroids treatment, the rates were 31.9% of patients treated with RINVOQ 45 mg once daily and 4.7% with placebo.
The partial adapted Mayo score (paMS) is composed of SFS and RBS. Clinical response per paMS is defined as a decrease of ≥1 point and ≥30% from Baseline and a decrease in RBS ≥1 or an absolute RBS ≤1. The pooled results of clinical response over time per paMS in UC-1 and UC-2 are shown in Figure 9. Onset of efficacy was rapid with a greater proportion of patients treated with RINVOQ 45 mg once daily achieving clinical response as early as Week 2 compared to placebo. (See Figure 9.)
Click on icon to see table/diagram/image
Endoscopic and Histologic Assessment: Normalization of the endoscopic appearance of the mucosa (endoscopic remission) was defined as ES of 0. At Week 8, a significantly greater proportion of patients treated with RINVOQ 45 mg once daily compared to placebo achieved endoscopic remission. Histologic improvement was defined as a decrease from Baseline in Geboes score. At Week 8, a significantly greater proportion of patients treated with RINVOQ 45 mg once daily compared to placebo achieved histologic improvement (see Table 21).
Biomarkers of Inflammation: In a pooled analysis of UC-1 and UC-2 at Week 8, high sensitivity CRP (hsCRP) decreased by 6.3 mg/L from Baseline (LS mean) in patients treated with RINVOQ 45 mg once daily vs 1.4 mg/L in patients treated with placebo. The rates of fecal calprotectin below 150 mg/kg for RINVOQ 45 once daily were 46.2% compared to 7.8% for placebo.
Quality of Life: Patients treated with RINVOQ 45 mg once daily compared to placebo demonstrated significantly greater and clinically meaningful improvements in health-related quality of life measured by the inflammatory bowel disease questionnaire (IBDQ), see Table 21.
Extended Induction: A total of 125 patients in UC-1 and UC-2 who did not achieve clinical response after 8 weeks of treatment with RINVOQ 45 mg once daily entered an 8-week open-label extended induction period. After the treatment of an additional 8 weeks (16 weeks total) of RINVOQ 45 mg once daily, 48.3% of patients achieved clinical response per aMS. Among patients who responded to treatment of 16-week RINVOQ 45 mg once daily, 35.7% and 66.7% of patients maintained clinical response per aMS and 19.0% and 33.3% of patients achieved clinical remission per aMS at Week 52 with maintenance treatment of RINVOQ 15 mg and 30 mg once daily, respectively.
Maintenance Study (UC-3): The efficacy analysis for UC-3 evaluated 451 patients who achieved clinical response per aMS with 8-week RINVOQ 45 mg once daily induction treatment. Patients were randomized to receive RINVOQ 15 mg, 30 mg or placebo once daily for up to 52 weeks.
The primary endpoint was clinical remission at Week 52. Secondary endpoints are listed in Table 22. (See Table 22.)
Click on icon to see table/diagram/image
Disease Activity and Symptoms: For patients who achieved clinical remission per aMS at induction, it was maintained at Week 52 by a significantly greater proportion of patients treated with RINVOQ 15 mg and 30 mg once daily compared to placebo. At Week 52, a greater proportion of patients treated with RINVOQ 15 mg and 30 mg once daily compared to placebo had no abdominal pain and no bowel urgency (see Table 22).
Clinical remission, defined as Partial Mayo score (consisting of SFS, RBS and PGA) ≤ 2 with no subscore >1, was achieved over time through Week 52 in more patients treated with both RINVOQ 15 mg and 30 mg once daily compared with placebo (see Figure 10).
Click on icon to see table/diagram/image
Endoscopic and Histologic Assessment: In UC-3, a significantly greater proportion of patients treated with RINVOQ 15 mg and 30 mg once daily compared to placebo achieved endoscopic remission at Week 52. Maintenance of endoscopic improvement at Week 52 (ES ≤1 without friability) was seen in a significantly greater proportion of patients treated with RINVOQ 15 mg and 30 mg once daily compared to placebo among patients who achieved endoscopic improvement at the end of induction (see Table 22).
Histologic improvement (decrease from baseline in Geboes score) was seen in a greater proportion of patients treated with RINVOQ 15 mg and 30 mg once daily at Week 52 compared to placebo (42.8% and 56.9% vs 20.6%).
Biomarkers of Inflammation: At Week 52, hsCRP was decreased by 3.9 mg/L and 5.6 mg/L from Baseline (LS mean) in patients treated with RINVOQ 15 mg and 30 mg once daily vs 0.1 mg/L in placebo. The percentage of patients with fecal calprotectin below 150 mg/kg for RINVOQ 15 mg and 30 mg once daily were 43.3% and 46.8%, compared to 12.1% for placebo.
Quality of Life: Patients treated with RINVOQ compared to placebo demonstrated significantly greater and clinically meaningful improvement in health-related quality of life as measured by inflammatory bowel disease questionnaire (IBDQ). See Table 22.
Pharmacokinetics: Upadacitinib plasma exposures are proportional to dose over the therapeutic dose range. Steady-state plasma concentrations are achieved within 4 days with minimal accumulation after multiple once-daily administrations.
Absorption: Following oral administration of upadacitinib extended-release formulation, upadacitinib is absorbed with a median T
max of 2 to 4 hours. Coadministration of upadacitinib with a high-fat meal had no clinically relevant effect on upadacitinib exposures (increased AUC by 29% and C
max by 39% to 60%). In clinical trials, upadacitinib was administered without regard to meals (see Dosage & Administration).
In vitro, upadacitinib is a substrate for the efflux transporters P-gp and BCRP.
Distribution: Upadacitinib is 52% bound to plasma proteins. Upadacitinib partitions similarly between plasma and blood cellular components, as indicated by the blood to plasma ratio of 1.0.
Metabolism: Upadacitinib metabolism is mediated by CYP3A4 with a potential minor contribution from CYP2D6. The pharmacologic activity of upadacitinib is attributed to the parent molecule. In a human radiolabeled study, unchanged upadacitinib accounted for 79% of the total radioactivity in plasma while the main metabolite (product of monooxidation followed by glucuronidation) accounted for 13% of the total plasma radioactivity. No active metabolites have been identified for upadacitinib.
Elimination: Following single dose administration of [
14C]-upadacitinib immediate-release solution, upadacitinib was eliminated predominantly as the unchanged parent substance in urine (24%) and faeces (38%). Approximately 34% of upadacitinib dose was excreted as metabolites. Upadacitinib mean terminal elimination half-life ranged from 9 to 14 hours.
Special populations: Renal impairment: Upadacitinib AUC was 18%, 33%, and 44% higher in subjects with mild (estimated glomerular filtration rate 60 to 89 mL/min/1.73 m
2), moderate (estimated glomerular filtration rate 30 to 59 mL/min/1.73 m
2), and severe (estimated glomerular filtration rate 15 to 29 mL/min/1.73 m
2) renal impairment, respectively, compared to subjects with normal renal function. Upadacitinib C
max was similar in subjects with normal and impaired renal function. For dosing in patients with renal impairment see Dosage & Administration.
Hepatic impairment: Mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment has no clinically relevant effect on upadacitinib exposure. Upadacitinib AUC was 28% and 24% higher in subjects with mild and moderate hepatic impairment, respectively, compared to subjects with normal liver function. Upadacitinib C
max was unchanged in subjects with mild hepatic impairment and 43% higher in subjects with moderate hepatic impairment compared to subjects with normal liver function. Upadacitinib was not studied in patients with severe (Child-Pugh C) hepatic impairment.
Paediatric population: The pharmacokinetics of upadacitinib have not yet been evaluated in paediatric patients with rheumatoid arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis and ulcerative colitis (see Dosage & Administration).
Upadacitinib pharmacokinetics and steady-state concentrations are similar for adults and adolescents 12 to 17 years of age with atopic dermatitis. The posology in adolescent patients 30 kg to < 40 kg was determined using population pharmacokinetic modelling and simulation.
The pharmacokinetics of upadacitinib in paediatric patients (< 12 years of age) with atopic dermatitis have not been established.
Intrinsic factors: Age, sex, body weight, race, and ethnicity did not have a clinically meaningful effect on upadacitinib exposure. Upadacitinib pharmacokinetics are consistent across patients with rheumatoid arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, atopic dermatitis and ulcerative colitis.
Toxicology: Preclinical safety data: Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology.
Upadacitinib, at exposures (based on AUC) approximately 4 and 10 times the clinical dose of 15 mg, 2 and 5 times the clinical dose of 30 mg, and 1.6 and 4 times the clinical dose of 45 mg in male and female Sprague-Dawley rats, respectively, was not carcinogenic in a 2-year carcinogenicity study in Sprague-Dawley rats. Upadacitinib was not carcinogenic in a 26-week carcinogenicity study in CByB6F1-Tg(-HRAS)2Jic transgenic mice.
Upadacitinib was not mutagenic or genotoxic based on the results of
in vitro and
in vivo tests for gene mutations and chromosomal aberrations.
Upadacitinib had no effect on fertility in male or female rats at exposures up to approximately 15 and 31 times the maximum recommended human dose (MRHD) of 45 mg in males and females, respectively, on an AUC basis in a fertility and early embryonic development study. Dose-related increases in foetal resorptions associated with post-implantation losses in this fertility study in rats were attributed to the developmental/teratogenic effects of upadacitinib. No adverse effects were observed at exposures below clinical exposure (based on AUC). Post-implantation losses were observed at exposures 8 times the clinical exposure at the MRHD of 45 mg (based on AUC).
In animal embryo-foetal development studies, upadacitinib was teratogenic in both rats and rabbits. Upadacitinib resulted in increases in skeletal malformations in rats at 1.6, 0.8 and 0.6 times the clinical exposure (AUC-based) at the 15, 30 and 45 mg (MRHD) doses, respectively. In rabbits an increased incidence of cardiovascular malformations was observed at 15, 7.6 and 5.6 times the clinical exposure at the 15, 30 and 45 mg doses (AUC-based), respectively. In a pre- and post-natal development study in pregnant female rats, oral upadacitinib administration at exposures approximately 1 times the MRHD of 45 mg resulted in no maternal effects, no effects on parturition, lactation or maternal behaviour and no effects on the offspring.
Following administration of upadacitinib to lactating rats, the concentrations of upadacitinib in milk over time generally paralleled those in plasma, with approximately 30-fold higher exposure in milk relative to maternal plasma. Approximately 97% of upadacitinib-related material in milk was the parent molecule, upadacitinib.
Administration of upadacitinib to juvenile Sprague-Dawley rats (from postnatal day 15 to 63) resulted in exposures and pharmacologic effects on the lymphoid system similar to those observed in adult rats. No adverse findings were observed in juvenile rats at exposures (AUC) approximately 9.4, 4.8 and 3.5 times the exposures at the clinical doses of 15, 30 and 45 mg, respectively (based on exposures in adult patients).